PR
DGX icon

Payden & Rygel’s Quest Diagnostics DGX Stock Holding History

Payden & Rygel’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15M Sell
76,600
-16,800
-18% -$3.26M 1.16% 33
2025
Q4 		$16.2M Sell
93,400
-800
-0.8% -$146K 1.12% 32
2025
Q3 		$18M Buy
94,200
+600
+0.6% +$106K 1.49% 27
2025
Q2 		$16.8M Buy
+93,600
New +$16.3M 1.39% 31

Other funds holding DGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Payden & Rygel's DGX Position: Q1 2026 in Review

Payden & Rygel reduced its Quest Diagnostics (DGX) stake by 18% in Q1 2026, selling an estimated $3.26M and leaving 76,600 shares worth $15M. The position accounts for 1.16% of the portfolio, ranked #33.

Payden & Rygel first reported a position in DGX in Q2 2025 and has held it in 4 quarters since. The position peaked at $18M in Q3 2025. 1,064 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • Payden & Rygel held 76,600 shares of Quest Diagnostics worth $15M as of Q1 2026.
  • Payden & Rygel sold 16,800 Quest Diagnostics shares in Q1 2026, an estimated $3.26M.
  • Quest Diagnostics made up 1.16% of Payden & Rygel's portfolio in Q1 2026, its #33 holding.
  • Payden & Rygel first reported a position in Quest Diagnostics in Q2 2025 and has held it in 4 quarters since.
  • Payden & Rygel's Quest Diagnostics position peaked at $18M in Q3 2025.
  • 1,064 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Payden & Rygel's 13F filing for Q1 2026, filed 12 May 2026.